ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0623

Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort

Marco Martinez1, Karen Roberts2, Rosana Quintana3, Marina Scolnik4, Carmen Funes Soaje5, Paula Alba6, Veronica Saurit7, Mercedes Garcia8, GUILLERMO ARIEL BERBOTTO9, Inés Verónica Bellomio10, Mario Eduardo Kerzberg11, Graciela Noemi Gomez12, Cecilia Pisoni13, Vicente Juarez14, Ana Malvar15, Antonio Da Silva16, ODIRLEI MONTICIELO17, Henrique Mariz18, Francinne Ribeiro19, Eduardo Borba20, Eloisa Bonfa20, Edgard dos Reis-Neto21, Iris Guerra Herrera22, Maria Loreto Massardo23, Gustavo Aroca-Martínez24, Lorena Gómez Escorcia25, Carlos Alberto Cañas26, Gerardo Quintana-Lopez27, Carlos Toro-Gutierrez28, Mario Moreno Alvarez29, MIGUEL SAAVEDRA30, Margarita Portela Hernández31, Hilda Fragoso-Loyo32, Luis H Silveira33, Ignacio García-De la Torre34, Carlos Abud-Mendoza35, Jorge Antonio Esquivel Valerio36, Maria Isabel Acosta37, Astrid Paats38, Claudia S. Mora-Trujillo39, Manuel Ugarte-Gil40, Armando Calvo41, Roberto Muñoz-Louis42, Martin Rebella43, Alvaro Danza44, José Gomez-Puerta45, Federico Zazzetti46, Ashley Orillion47, Guillermo Pons-Estel3 and Ingris del Pilar Pelaez Ballestas48, 1HGSZ No 9, Instituto Mexicano del Seguro Social, San Luis Potosí, México, Rioverde, Mexico, 2Instituto de Investigación, Rosario, Argentina, Wyomissing, PA, 3Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 6Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, 7Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, 8Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, 10Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, 11Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, 12Instituto de Investigaciones Médicas Dr. Alfredo Lanari, Don Torcuato, Argentina, 13CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, 14Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, 15Organización Médica de Investigación, Buenos Aires, Argentina, 16Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Holzkirchen, Germany, 17Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, 18Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, 19Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, 20Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 21Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, 22Hospital del Salvador Santiago de Chile, Santiago, Chile, santiago, Chile, 23Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, 24Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, 25Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, 26Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, 27Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogota, Colombia, 28Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, 29Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, 30Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, 31Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, 32Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, 33Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, 34Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, 35Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, 36Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, 37Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, 38Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, 39Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, 40Universidad Cientifica del Sur, Lima, Peru, 41Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, 42Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, 43Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, 44Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, 45Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, 46Johnson & Johnson, Horsham, PA, USA, Ambler, PA, 47Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 48Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico, Mexico, Mexico

Meeting: ACR Convergence 2025

Keywords: socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Evidence from high-income countries suggests that socioeconomic status (SES) and environmental factors influence SLE outcomes, yet data from Latin America remain limited. The objective of this research was to evaluate, across three levels (individual, regional, and national), whether socioeconomic and environmental factors impact the clinical presentation of SLE in the GLADEL 2.0 cohort.

Methods: We analyzed data from 1,083 patients with SLE enrolled in the GLADEL 2.0 cohort across 10 Latin American countries. All patients fulfilled the 1982/1997 American College of Rheumatology (ACR) or 2012 Systemic Lupus International Cooperating Clinics (SLICC) classification criteria. Clinical outcomes were disease activity (SLEDAI-2K), organ involvement (renal, hematologic, cutaneous, musculoskeletal), and organ damage (SLICC/ACR damage index; SDI). Variables were structured into three levels: Level 1 (individual), Level 2 (state/province), and Level 3 (national). Multilevel analyses included sociodemographic variables, environmental exposure to air pollutants (PM2.5, PM10, NO2), and contextual indicators (income, unemployment, distribution of income or wealth through the Gini index, CO2 emissions). Statistical analysis included cluster analysis (Ward’s method) and principal component analysis (PCA).

Results: Five clusters emerged based on socioeconomic and environmental determinants. Cluster two (urban, high-income, low inequality) exhibited low damage (SDI [mean ± SD] 0.66 ± 0.9) and high disease activity (SLEDAI [mean ± SD] 13.0 ± 9.2). Conversely, Cluster four (middle-low SES, high inequality, high NO2 exposure) demonstrated high disease impact (SDI [mean ± SD] 1.06 ± 1.4) and greatest work productivity loss (36.1%). Cluster three (low-income, low pollution) presented the highest accumulated damage (mean SDI [mean ± SD] 1.73 ± 1.95). Environmental exposures varied significantly; Cluster five showed the highest CO2 emissions and solar irradiance, while Cluster three had the lowest environmental burden. PCA showed that clinical manifestations, disease activity and chronicity were different across clusters. The figure highlights the separation of the characteristics according to the three principal components.

Conclusion: Socioeconomic and environmental factors at individual, regional, and national levels influence the cumulative clinical manifestations and patient-reported outcomes in SLE. Our findings underscore the role of social vulnerability and environmental stressors as potential modifiers of SLE phenotype in Latin America, highlighting the need for context-sensitive interventions and policies to mitigate health inequities.

Supporting image 1Figure. Three-dimensional representation of the first three principal components, showing the five clusters of SLE patients derived from socioeconomic and environmental variables


Disclosures: M. Martinez: None; K. Roberts: None; R. Quintana: None; M. Scolnik: AstraZeneca, 2, 5, 6, GSK, 1, 5, 6, Janssen, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 1, 5, 6; C. Funes Soaje: None; P. Alba: None; V. Saurit: None; M. Garcia: None; G. BERBOTTO: None; I. Bellomio: None; M. Kerzberg: None; G. Gomez: None; C. Pisoni: None; V. Juarez: None; A. Malvar: Bristol-Myers Squibb(BMS), 2, F. Hoffman-La Roche Ltd/Genentech, Inc., 2, GlaxoSmithKline (GSK), 2, Kezar, 2, Novartis, 2, Pfizer, 2; A. Da Silva: None; O. MONTICIELO: None; H. Mariz: None; F. Ribeiro: None; E. Borba: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (303378/2022-0), 5, GlaxoSmithKlein(GSK), 5; E. Bonfa: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) #305242/2019-9, 5, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP) (2022/12925-8), 5, GlaxoSmithKlein(GSK), 5; E. dos Reis-Neto: None; I. Guerra Herrera: None; M. Massardo: None; G. Aroca-Martínez: None; L. Gómez Escorcia: None; C. Cañas: None; G. Quintana-Lopez: None; C. Toro-Gutierrez: None; M. Moreno Alvarez: None; M. SAAVEDRA: None; M. Portela Hernández: None; H. Fragoso-Loyo: None; L. Silveira: None; I. García-De la Torre: None; C. Abud-Mendoza: None; J. Esquivel Valerio: None; M. Acosta: None; A. Paats: None; C. Mora-Trujillo: None; M. Ugarte-Gil: AstraZeneca, 1, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 6, Janssen, 5, technofarma, 1; A. Calvo: None; R. Muñoz-Louis: None; M. Rebella: None; A. Danza: None; J. Gomez-Puerta: AbbVie/Abbott, 6, AstraZeneca, 6, GlaxoSmithKlein(GSK), 6, Pfizer, 6; F. Zazzetti: Johnson & Johnson, 3, 11; A. Orillion: Johnson & Johnson, 3, 11; G. Pons-Estel: AstraZeneca, 1, 6, GlaxoSmithKlein(GSK), 1, 6, Janssen, 1, 6; I. Pelaez Ballestas: None.

To cite this abstract in AMA style:

Martinez M, Roberts K, Quintana R, Scolnik M, Funes Soaje C, Alba P, Saurit V, Garcia M, BERBOTTO G, Bellomio I, Kerzberg M, Gomez G, Pisoni C, Juarez V, Malvar A, Da Silva A, MONTICIELO O, Mariz H, Ribeiro F, Borba E, Bonfa E, dos Reis-Neto E, Guerra Herrera I, Massardo M, Aroca-Martínez G, Gómez Escorcia L, Cañas C, Quintana-Lopez G, Toro-Gutierrez C, Moreno Alvarez M, SAAVEDRA M, Portela Hernández M, Fragoso-Loyo H, Silveira L, García-De la Torre I, Abud-Mendoza C, Esquivel Valerio J, Acosta M, Paats A, Mora-Trujillo C, Ugarte-Gil M, Calvo A, Muñoz-Louis R, Rebella M, Danza A, Gomez-Puerta J, Zazzetti F, Orillion A, Pons-Estel G, Pelaez Ballestas I. Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/cluster-analysis-of-socioeconomic-and-environmental-determinants-modifying-activity-chronicity-and-clinical-manifestations-of-systemic-lupus-erythematosus-in-the-gladel-2-0-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-analysis-of-socioeconomic-and-environmental-determinants-modifying-activity-chronicity-and-clinical-manifestations-of-systemic-lupus-erythematosus-in-the-gladel-2-0-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology